DGIdb - NAVARIXIN Drug Record

NAVARIXIN chembl:CHEMBL216981

Alternate Names:

PS-291822
SCH-527123
NAVARIXIN
MK-7123

Drug Info:

FDA Approval	not approved
Drug Class	small molecule
Drug Indications	for treatment of chronic obstructive pulmonary disorder (COPD)

(1 More Sources)

Publications:

Dwyer MP et al., 2006, Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist., J Med Chem

NAVARIXIN MADCAM1

Interaction Score: 10.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
NAVARIXIN CXCR2

Interaction Score: 9.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name SCH-527123, PS-291822, PS-938285

Novel drug target Novel Target

Mechanism of Interaction Interleukin-8 receptor B antagonist

PMIDs:
17181143

Sources:
DTC TdgClinicalTrial ChemblInteractions TTD
NAVARIXIN CXCR1

Interaction Score: 8.24

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name SCH-527123, PS-291822, PS-938285

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

TdgClinicalTrial: SCH-527123
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of chronic obstructive pulmonary disorder (COPD)

Drug Class small molecule

FDA Approval not approved

Publications:

DTC: NAVARIXIN

Version: 02-September-2020

Alternate Names:

CHEMBL216981 ChEMBL Drug ID

Drug Info:

Publications:

Dwyer MP et al., 2006, Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist., J Med Chem

TTD: SCH-527123
- Version: 2020.06.01
Alternate Names:

D00QKI TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL216981
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL216981
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

NAVARIXIN Drug Record

NAVARIXIN chembl:CHEMBL216981

Alternate Names:

Drug Info:

Publications:

NAVARIXIN MADCAM1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD

NAVARIXIN CXCR2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name SCH-527123, PS-291822, PS-938285

Novel drug target Novel Target

Mechanism of Interaction Interleukin-8 receptor B antagonist

PMIDs:
17181143

Sources:
DTC TdgClinicalTrial ChemblInteractions TTD

NAVARIXIN CXCR1

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name SCH-527123, PS-291822, PS-938285

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

TdgClinicalTrial: SCH-527123

Alternate Names:

Drug Info:

Drug Indications for treatment of chronic obstructive pulmonary disorder (COPD)

Drug Class small molecule

FDA Approval not approved

Publications:

DTC: NAVARIXIN

Alternate Names:

CHEMBL216981 ChEMBL Drug ID

Drug Info:

Publications:

Dwyer MP et al., 2006, Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist., J Med Chem

TTD: SCH-527123

Alternate Names:

D00QKI TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL216981

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL216981

Alternate Names:

Drug Info:

Publications:

Trial Name	SCH-527123, PS-291822, PS-938285
Novel drug target	Novel Target
Mechanism of Interaction	Interleukin-8 receptor B antagonist

NAVARIXIN Drug Record

NAVARIXIN chembl:CHEMBL216981

Alternate Names:

Drug Info:

Publications:

NAVARIXIN MADCAM1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: TTD

NAVARIXIN CXCR2

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name SCH-527123, PS-291822, PS-938285 Novel drug target Novel Target Mechanism of Interaction Interleukin-8 receptor B antagonist

PMIDs: 17181143

Sources: DTC TdgClinicalTrial ChemblInteractions TTD

NAVARIXIN CXCR1

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name SCH-527123, PS-291822, PS-938285 Novel drug target Novel Target

PMIDs: None found

Sources: TdgClinicalTrial TTD

TdgClinicalTrial: SCH-527123

Alternate Names:

Drug Info: Drug Indications for treatment of chronic obstructive pulmonary disorder (COPD) Drug Class small molecule FDA Approval not approved

Publications:

DTC: NAVARIXIN

Alternate Names: CHEMBL216981 ChEMBL Drug ID

Drug Info:

Publications: Dwyer MP et al., 2006, Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist., J Med Chem

TTD: SCH-527123

Alternate Names: D00QKI TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL216981

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL216981

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name SCH-527123, PS-291822, PS-938285

Novel drug target Novel Target

Mechanism of Interaction Interleukin-8 receptor B antagonist

PMIDs:
17181143

Sources:
DTC TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name SCH-527123, PS-291822, PS-938285

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial TTD

Drug Info:

Drug Indications for treatment of chronic obstructive pulmonary disorder (COPD)

Drug Class small molecule

FDA Approval not approved

Alternate Names:

CHEMBL216981 ChEMBL Drug ID

Publications:

Dwyer MP et al., 2006, Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist., J Med Chem

Alternate Names:

D00QKI TTD Drug ID